Can Qualcomm’s 12% Surge Survive Its Own Guidance?

NEW YORK — Qualcomm opened Thursday’s session up more than 12%, the clearest single-stock story at the bell — but the driver was not what most analysts had circled on their earnings preview sheets.

The broader tape opened constructively. The S&P 500 gained 0.4%, building on a previous close of 7,135.95. The Nasdaq Composite climbed 0.6% from its 24,673.24 prior close. The Dow Jones Industrial Average added roughly 250 points, or 0.5%. All three major indices are on track to close out April with gains that would rank among the strongest months in years — the Nasdaq is pacing for a 14% April advance, its best since April 2020, while the S&P 500 sits above 9% month-to-date, approaching its best month since November 2020.

A Month That Defied the Doubters

April opened under the shadow of tariff escalation fears, Federal Reserve uncertainty, and a first-quarter GDP report that the market expected to disappoint. What followed was a grinding, then accelerating, recovery that caught many defensively-positioned funds off-sides. As we explored in Will Today’s GDP and PCE Data Break the Stalemate?, the macro data backdrop was genuinely ambiguous — yet equities found traction anyway, powered largely by earnings that cleared a lowered bar and by AI-linked capital spending that has not materially decelerated despite rhetoric to the contrary.

The Dow’s 6%-plus April gain is its strongest monthly print since November 2024. That breadth — Dow, S&P, and Nasdaq all posting substantial monthly gains simultaneously — suggests this has not been a narrow momentum move. Still, the durability of the rally from here depends heavily on whether the earnings season’s second half matches the first. Today’s two headline movers, Qualcomm and Eli Lilly, represent very different kinds of beats, and the market’s reaction to each tells a nuanced story.

Data Visual

Qualcomm Quarterly Revenue Trend — Q2 FY2026 in Context

Shows Qualcomm’s reported revenue across recent quarters to frame how the Q2 FY2026 result and weak Q3 guidance fit the trajectory traders are pricing.

Values in $B

Opening Bell Standout — Qualcomm: AI Optionality Priced as AI Revenue

Qualcomm (QCOM) opened at $174.97, up 12.16% from its prior close of $156.00. The company reported fiscal second-quarter revenue of $10.6 billion — down 3% year over year but in line with its own guidance midpoint — and diluted earnings per share of $6.88, a figure that reflected significant year-over-year EPS expansion. Those numbers alone would not have moved the stock 12%. What moved it was this: management disclosed that a leading hyperscaler custom silicon engagement is on track for initial shipments later this calendar year.

That disclosure landed in a market that is actively hunting for the next leg of the AI semiconductor trade beyond Nvidia. Qualcomm has spent the better part of two years positioning its custom chip capabilities as a credible alternative to merchant silicon for large cloud customers. One line in an earnings release should not move a $170 billion company by $18 billion in market cap at the open — but it did. The bears would note that June-quarter revenue guidance of $9.6 billion at the midpoint came in below the FactSet consensus, meaning the underlying handset and IoT business is still softening on a sequential basis. The hyperscaler disclosure is real, but it is early-stage — and the market is paying for it at full price today.

The analyst community was already split on QCOM heading into earnings. Consensus carried 11 Buy, 22 Hold, and 3 Sell ratings with an average price target of approximately $150–$160 — below where the stock opened Thursday morning. That means the majority of analysts on the street were underweight or neutral heading into a 12% gap-up. Short covering almost certainly contributed to the early price action. The question is whether fundamental upgrades follow, or whether the stock mean-reverts once the initial enthusiasm fades.

Eli Lilly Resets the GLP-1 Baseline

Eli Lilly opened at $872.28, up nearly 7%, after reporting first-quarter 2026 results that were not just a beat — they were a structural reset of what the GLP-1 market can generate at scale. Q1 revenue came in at $19.8 billion against a consensus of $17.8 billion — a $2 billion upside surprise on a quarterly basis. Mounjaro sales reached $8.66 billion, up 125% year over year. Zepbound contributed $4.16 billion, up 80% year over year.

Those growth rates are decelerating from 2025 peaks in percentage terms — which is mathematically inevitable as the base grows — but the absolute dollar volumes are exceeding every model that was built for this market even 12 months ago. Lilly raised its full-year 2026 revenue guidance to $82–85 billion and lifted non-GAAP EPS guidance to $35.50–$37.00. Both ranges sit above the FactSet average estimates that existed before the print. The company also reported adjusted earnings per share of $8.55 against a Zacks consensus of $7.06 — a 21% beat on the bottom line. This is the kind of quarter that does not invite second-guessing.

The bear case on LLY has long rested on competitive pressure from Novo Nordisk and pipeline execution risk. Neither of those concerns is resolved by one quarter. But at $872, the stock is pricing in continued dominance — and today’s data supports that bet more convincingly than it did 24 hours ago. Those tracking the broader macro picture should note that Lilly’s results are relevant beyond the healthcare sector: a company generating nearly $80 billion in annualized revenue from two drugs is a meaningful signal about consumer and insurance willingness to pay at scale. As we covered in Is the Economy Slowing Faster Than the Fed Is Willing to Admit?, discretionary and healthcare spending data have been sending mixed signals — Lilly’s numbers push back on the slowdown narrative in at least one corner of the market.

Data Visual

Eli Lilly Key Drug Sales — Q1 2026 vs. Year-Ago Quarter

Compares Mounjaro and Zepbound revenue in Q1 2026 against Q1 2025 to show the scale of the year-over-year growth driving LLY’s earnings beat and guidance raise.

Values in $B

For those tracking the AI capital spending thread, it is also worth connecting Qualcomm’s hyperscaler disclosure to the broader question of where the next wave of AI infrastructure investment flows. We examined this directly in Did Big Tech Just Blink on AI Spending? — the short answer is no, the hyperscalers have not blinked, and Qualcomm’s disclosure today is consistent with that thesis. Custom silicon engagement does not happen unless the customer is committed to the infrastructure buildout at scale.

The Levels That Will Define the First Hour

On Qualcomm, the gap needs to hold above $168 to signal that this is institutional accumulation rather than a retail momentum squeeze. A fade below that level would put the implied-move ceiling from options pricing in the rearview mirror and signal that the initial reaction was overdone. Conviction longs would want to see the stock consolidate in the $170–$175 range with declining volume — that is a healthy digestion of a gap. A high-volume reversal below $168 tells a different story entirely.

For Eli Lilly, the $860 level is the key near-term support. The stock has been range-bound for most of April, and today’s open represents a clean breakout. If it holds $860 through the first hour, the setup favors continuation toward $890–$900. A failure to hold $860 into midday would suggest the beat was already partially priced and that sellers are using the gap as an exit.

At the index level, the S&P 500 at 7,135 plus today’s 0.4% gain puts it near 7,165. A move through 7,200 intraday would be a technically significant milestone and could trigger additional systematic buying. The month-end dynamic matters here too — April 30 is the last session of the month, meaning portfolio rebalancing flows, window dressing, and options expiration mechanics are all active simultaneously. That adds noise to intraday price action that should not be over-interpreted as directional signal.

What the First Hour Will Actually Settle

Month-end sessions carry structural noise that makes it harder to read intraday moves as signals. Rebalancing flows, window dressing by fund managers, and options mechanics around monthly expiration all interact with earnings-driven price action in ways that can distort both direction and volume. The clean read on whether Qualcomm’s open is a genuine re-rating or a momentum trap will come from the stock’s behavior between 10:30 and 11:30 AM ET — not the first five minutes after the bell.

Eli Lilly’s story is cleaner. The fundamental data is unambiguous, the guidance raise is real, and the stock has been in a multi-month consolidation that gives today’s move room to run. The more interesting question for the next several weeks is whether the GLP-1 revenue trajectory holds through Q2 2026 or whether comparisons begin to bite harder. Today’s open answered April’s question. May’s question is already forming.

The S&P 500’s best April in six years does not guarantee a strong May — in fact, historically, months following outsized gains often see consolidation as positioning normalizes. The level to watch into the close today is whether the S&P holds its gains or fades into the final hour, which would tell you whether month-end buying flows were front-loaded or still coming. Either way, the earnings season has delivered enough upside surprises to justify the index’s move — the harder task is justifying further gains from here without a new catalyst. For a deeper look at the structural underpinnings of this rally, see Is the S&P 500’s Record Run Built on Solid Ground?